HALO Financials

Income Statement
MetricQ2 2026Q1 2026Q4 2025Q3 2025Q2 2025
Revenue
481.0M
+27.7%
376.7M
-16.6%
451.8M
+27.5%
354.3M
+8.8%
325.7M
Cost of Revenue
79.2M
-0.1%
79.2M
+0.6%
78.8M
+42.6%
55.2M
+19.2%
46.4M
Gross Profit
401.8M
+35.1%
297.5M
-20.2%
373.0M
+24.7%
299.0M
+7.0%
279.4M
Operating Expenses
114.2M
+1.1%
113.0M
-72.9%
417.2M
+414.4%
81.1M
+5.4%
76.9M
R&D
27.7M
+8.2%
25.6M
-19.9%
31.9M
+84.9%
17.3M
-1.7%
17.5M
SG&A
57.0M
-1.5%
57.9M
-24.9%
77.0M
+67.1%
46.1M
+10.8%
41.6M
Operating Income
287.7M
+55.9%
184.5M
+517.5%
-44191000
-120.3%
217.9M
+7.6%
202.4M
EBITDA
321.6M
+47.4%
218.3M
-18.4%
267.4M
+12.2%
238.3M
+6.9%
222.9M
Net Income
229.9M
+53.2%
150.0M
+206.0%
-141591000
-180.8%
175.2M
+6.1%
165.2M
EPS (Basic)
$1.96
+54.3%
$1.27
+205.8%
$-1.20
-180.5%
$1.49
+9.6%
$1.36
EPS (Diluted)
$1.90
+55.7%
$1.22
+205.2%
$-1.16
-181.1%
$1.43
+7.5%
$1.33
Shares (Diluted)
121.2M
-1.4%
122.9M
+0.3%
122.5M
+0.1%
122.3M
-1.5%
124.2M
Halozyme Therapeutics (HALO) โ€” Financials